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Abstract
Background: Managed care organizations use a variety of strategies to reduce the cost and improve the quality of
medication use. The effectiveness of such policies is not well understood. The objective of this research was to update
a previous systematic review of interventions, published between 1966 and 2001, to improve the quality and efficiency
of medication use in the US managed care setting.
Methods: We searched MEDLINE and EMBASE for publications from July 2001 to January 2007 describing interventions
targeting drug use conducted in the US managed care setting. We categorized studies by intervention type and adequacy
of research design using commonly accepted criteria. We summarized the outcomes of well-controlled strategies and
documented the significance and magnitude of effects for key study outcomes.
Results: We identified 164 papers published during the six-year period. Predominant strategies were: educational
interventions (n = 20, including dissemination of educational materials, and group or one-to-one educational outreach);
monitoring and feedback (n = 22, including audit/feedback and computerized monitoring); formulary interventions (n =
66, including tiered formulary and patient copayment); collaborative care involving pharmacists (n = 15); and disease
management with pharmacotherapy as a primary focus (n = 41, including care for depression, asthma, and peptic ulcer
disease). Overall, 51 studies met minimum criteria for methodological adequacy. Effective interventions included one-to-
one academic detailing, computerized alerts and reminders, pharmacist-led collaborative care, and multifaceted disease
management. Further, changes in formulary tier-design and related increases in copayments were associated with
reductions in medication use and increased out-of-pocket spending by patients. The dissemination of educational
materials alone had little or no impact, while the impact of group education was inconclusive.
Conclusion: There is good evidence for the effectiveness of several strategies in changing drug use in the managed care
environment. However, little is known about the cost-effectiveness of these interventions. Computerized alerts showed
promise in improving short-term outcomes but little is known about longer-term outcomes. Few well-designed,
published studies have assessed the potential negative clinical effects of formulary-related interventions despite their
widespread use. However, some evidence suggests increases in cost sharing reduce access to essential medicines for
chronic illness.
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Background
Managed care organizations (MCOs) are the predominant
form of health insurance coverage in the United States.
MCOs provide health care to over 160 million enrollees
and almost 90% of physicians have at least one managed
care contract [1]. By enrollment numbers in 2005, pre-
ferred provider organizations (PPOs) are the most com-
mon form of managed care (61%) followed by health
maintenance organizations (HMOs; 21%), and point-of-
service and conventional plans cover a small portion of
the insured (15% and 3%, respectively) [1].
Healthcare payers, including MCOs, grapple with the
challenge of providing access to essential care that
improves health outcomes in the face of increasing need
to control healthcare costs. Growth in pharmaceutical
spending over the past decade is partly due to increased
ingredient costs per prescription, higher levels of utiliza-
tion, and changes in the drugs being prescribed [2]. A vari-
ety of strategies have been used by MCOs to contain
escalating drug expenditures and to improve the quality of
medication use.
Drug formularies are a common cost containment strat-
egy used by healthcare payers. Formularies are lists of pre-
ferred pharmaceutical products covered by an institution
within various therapeutic categories [3]. Health plans
continue to switch from 1-tier plans (same copayment for
all medications under coverage) and 2-tier plans (a lower
copayment for generic drugs and a higher copayment for
brand-name drugs) to 3-tier plans that include a third,
higher copayment(s) for non-preferred brand-name med-
ications. Such 3-tier plans are now the dominant man-
aged care formulary structure [4]. Since 2004, a number of
plans have created a fourth tier of cost-sharing for specific
types of drugs such as lifestyle medications and biologics
[5]. Patient copayments for prescription drugs are another
strategy which aims to sensitize patients to the costs of
medications so as to discourage use of non-essential med-
ications. Copayments in health plans have risen substan-
tially over the past decade [5]. From 2000 to 2006, the
average copayment for generic drugs increased 57% (from
$7 to $11), while copayments for preferred brand-name
drugs increased 85% (from $13 to $24) and copayments
for non-preferred brand-name drugs increased 123%
(from $17 to $38) [5]. In addition, MCOs attempt to
influence medicines use and improve quality of care
through educational programs, prescribing feedback, and
computer-based information system [6]. Disease manage-
ment programs are also used to improve care delivery and
health outcomes for patients with specific chronic ill-
nesses [6].
The validity and reliability of information about the effec-
tiveness and unintended consequences of drug-related
interventions depends heavily on the strength of the
research design [7,8]. By critically appraising studies, sys-
tematic reviews can provide useful and more objective
information to clinicians, patients, and policy makers. In
our previous systematic review of studies evaluating drug-
related interventions in MCOs published prior to June
2001 [6], we found a number of consistently effective
interventions. These included participatory clinical guide-
line development, one-to-one and group educational out-
reach, and enhanced patient-specific feedback.
Dissemination of educational materials alone and aggre-
gate feedback to clinicians about their patients were
shown to be ineffective. These findings are consistent with
other reviews evaluating interventions outside the man-
aged care setting [7,9,10]. We also found that dissemina-
tion of educational materials with drug samples – a
technique used widely by the pharmaceutical industry to
influence prescribing and patient demand – was effective
in changing medication use, while disease management
showed promise in improving short-term outcomes in the
management of diabetes and depression [6]. Importantly,
methodologically acceptable studies of the impact of for-
mulary changes and financial strategies as drug cost-con-
tainment policies were too few to be included in our
previous review. This represented a significant gap in
knowledge because such policies are widely used to con-
trol pharmaceutical expenditures and it is likely they have
negative as well as positive impacts on clinical outcomes.
At that time there was also a paucity of evidence of the
effectiveness of interventions in more 'lightly' managed
care.
The purpose of this review is to update our previous sys-
tematic review of interventions to improve medication
use in MCOs [6]. Specifically, we aim to describe interven-
tions to improve the quality and efficiency of medication
use in the US managed care setting published between
July 2001 and January 2007; detail key features of meth-
odologically adequate studies; summarize intervention
effects; and identify the most successful types of interven-
tions.
Methods
Search Strategy
We performed a systematic review of published interven-
tions conducted in MCOs to reduce pharmaceutical costs
or improve use of medicines. We searched MEDLINE and
EMBASE from 2001 through January 2007 using a combi-
nation of search terms describing the study setting (e.g.
managed care programs, health maintenance organiza-
tions, preferred provider organizations), methodology
(e.g. randomized controlled trials, intervention studies,
program evaluation, health services research, comparative
studies), intervention types (e.g. formulary, education,
practice guidelines, cost containment, quality assurance,BMC Health Services Research 2008, 8:75 http://www.biomedcentral.com/1472-6963/8/75
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risk sharing, reimbursement mechanisms), drug use (e.g.
prescription and non-prescription drugs, drug therapy,
drug utilization, drug monitoring, drug substitution), and
clinician practice patterns (e.g. physician, clinicians, pro-
vider, practitioner, physician practice patterns, prescribing
practice). The reference lists of studies identified in this
way were reviewed to identify studies that our search strat-
egy may have missed. The search retrieved all studies pub-
lished since January 2001 including some of those
analyzed in our previous review.
A total of 2899 articles were identified by the search. Two
investigators (CYL, SAP) each independently reviewed
half of the study abstracts. Studies were included in the
review if they met the following criteria: were published
between July 2001 and January 2007 (inclusive), con-
ducted in the US managed care setting including all forms
of HMOs, PPOs, and independent practice associations
(IPAs); described intervention(s) targeting medication
use, including over-the-counter medications, herbals, or
vitamins; included a clear description of methods; and
measured drug-related outcomes. Disease management
interventions focusing on pharmacotherapy were also
considered. We have also included in the current review
the four methodologically adequate formulary interven-
tions not reported in our previous review. Due to the
rapid growth in research on this topic since 2001, there
are now sufficient studies to draw more valid conclusions.
Clinical effectiveness trials and cost effectiveness studies
of medications, descriptive studies, and those examining
vaccinations were excluded.
Rating Study Quality
We reviewed the methodological adequacy of studies
identified by our search. Based on the ability of specific
research designs to control adequately for common
threats to internal validity [8,11,12], our definition for
methodologically adequate studies included: randomized
controlled trials (RCTs); pre-post studies with non-rand-
omized comparison group(s); and interrupted time series
analysis with or without comparison group. Interrupted
time series designs examine changes in outcomes of inter-
est using multiple observations (at least 4 by our defini-
tion) before and after an intervention [12]. Research
designs deemed methodologically inadequate were pre-
post studies without a comparison group, non-rand-
omized post-only studies, and cross-sectional studies.
Such designs have been shown to produce invalid results
in previous research [7,8]. In addition, studies were only
included if each comparison group included at least 20
subjects to ensure the reliability of results.
Data extraction
We extracted key features of the characteristics, methods,
and outcomes of methodologically adequate studies
using a standardized data extraction tool. Key features
included: setting, objective/s, health condition/s
addressed, intervention components, predominant inter-
vention strategy, intervention target/s, and up to three pri-
mary outcome measures reported by the authors. To check
reliability of data extraction, two investigators (CYL, SAP)
independently extracted data from the included studies
and calculated effect sizes of outcome measures for one-
third of the studies in this review.
Results
One hundred and fifty one published studies met our ini-
tial inclusion criteria, of which 31% met our criteria for
minimally acceptable methodology. The majority of these
studies (45%) were conducted in staff, group and mixed
model settings and 6 studies were conducted in IPAs, net-
work model organizations, and Medicare or Medicaid
MCOs; the remaining studies (40%) did not provide
detailed information on the type of managed care setting.
We classified studies according to predominant strategy
and key intervention components [Table 1]. In order of
frequency, predominant strategies were formulary-related
interventions (40% of studies), disease management
(25%), monitoring and feedback (13%), educational
interventions (12%), and collaborative care involving
pharmacists (10%).
The primary interventions tested in studies that met crite-
ria for methodological adequacy were: educational inter-
ventions (7), monitoring and feedback (16), formulary-
related interventions (15 including 4 published prior to
July 2001), collaborative care involving pharmacists (5),
and disease management (8). We categorized methodo-
logically adequate interventions involving financial
incentives as formulary-related interventions because the
predominant focus of these studies was to assess the
effects of differential patient copayment associated with
tiered formularies. Additional file 1 summarizes the key
aspects of the 51 methodologically acceptable studies.
Educational interventions
i. Dissemination of Educational Materials Alone
The dissemination of educational materials alone (e.g.
newsletters, clinical guidelines, and audiovisual materi-
als) is used commonly as a behavior change strategy,
although this approach has been shown repeatedly to be
ineffective as a stand-alone intervention [6,9]. This strat-
egy was one arm of an RCT conducted by Majumdar et al
[13] in the form of a clinical guideline and 'toolkit' (a list
of eligible patients and patient educational materials);
another arm of this trial evaluated the impact of group
education (discussed below). Not surprisingly, the mate-
rials only intervention failed to increase the testing and
treatment of Helicobacter pylori (HP) infection or toBMC Health Services Research 2008, 8:75 http://www.biomedcentral.com/1472-6963/8/75
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reduce proton pump inhibitor and histamine-2 blocker
prescribing.
ii. One-to-One Education
One-to-one educational outreach (often referred to as aca-
demic detailing) has been shown to be an effective tech-
nique to change many aspects of physician behavior,
particularly medication use [14,15]. Simon et al [16] dem-
onstrated that one-to-one education sessions delivered by
peer leaders increased guideline adherence and the use of
diuretics and beta-blockers for hypertension.
Two studies evaluated the impact of one-to-one patient
counseling by pharmacists. One intervention successfully
decreased mortality rates in patients using drugs with a
narrow therapeutic index; hospitalizations were also
reduced by both brief and detailed pharmacist counseling,
although the effects were not significant [17]. Results from
another study [18] showed that detailed pharmacist coun-
seling on adherence to medications with follow-up tele-
phone calls did not increase the rate of eradication of HP
infection over pharmaceutical treatment without coun-
seling, but it did increase patient satisfaction.
iii. Group Education
Group education relies on either didactic or problem-
based approaches to influence behavior [7]. In our review
peer leader education in small practice-based groups was
shown to increase testing and treatment for HP infection;
however, it was unsuccessful in reducing the use of proton
pump inhibitors or histamine-2 blockers [13]. Simon et al
[16] demonstrated that an intervention involving group
academic detailing improved antihypertensive prescrib-
ing; individual academic detailing was more successful
than group visits in increasing the use of diuretics and
beta-blockers as recommended by clinical guidelines.
There is some evidence that both group and individual
detailing interventions are cost-saving [16,19]. Another
study using group academic detailing by psychiatrists and
interactive discussions to improve depression manage-
ment by primary care physicians demonstrated no signif-
icant increase in antidepressant prescribing or treatment
duration at 12 months post-intervention [20]. A signifi-
cant reduction in antibiotic prescription rates was
achieved over a 3-year period by using a multifaceted
intervention comprised of peer leader education sessions
to practitioners, provision of mailed educational materi-
als (based on materials from the Centers for Disease Con-
trol and Prevention) to parents of young children, and
dissemination of key educational messages via radio,
newspaper, television and pamphlets in hospitals, clinics,
and pharmacies directed at the general public [21].
Monitoring and feedback
i. Prescribing audit and feedback
Audit and feedback interventions report physicians' past
or current clinical practice, usually in relation to the prac-
tice of peers or accepted standards. Audit and feedback
can achieve small to moderate improvements in physi-
cians' practice [22,23]. Four studies in this review used
prescriber feedback combined with educational materials
to change medication use. Providing clinical recommen-
dations to physicians with annual mailed peer-compari-
son feedback over a four-year period achieved small
increases in the use of statins, beta-blockers, and angi-
otensin-converting enzyme inhibitors among patients
with coronary heart disease [24]. Simon et al [25] demon-
strated that internet-based feedback to residents on their
prescribing practices complemented by educational mate-
rials did not increase the proportion of diabetic patients
receiving glycemic monitoring or change antihypertensive
prescribing. However, residents were required to actively
access a password-protected personalized website to be
exposed to the intervention [25].
Table 1: Studies identified according to key features and predominant intervention strategy
Educational Monitoring & 
Feedback
Formulary* Collaborative Care 
Involving Pharmacists
Disease 
Management†
TOTAL
All studies 20 22 66 15 41 164
Methodologically 
acceptable studies
71 6 1 5 5 8 5 1
RCT 5 10 2 3 7 27
Interrupted time series 0 5 5 0 0 10
Pre/post studies with 
comparison
218 2 1 1 4
Interventions in 
methodologically 
acceptable studies‡
17 18 21 5 8 69
* published studies from 1966 through January 2007.
† Only studies with pharmacotherapy as a primary focus.
‡ Studies may have examined more than one intervention and multiple studies may have examined the same interventionBMC Health Services Research 2008, 8:75 http://www.biomedcentral.com/1472-6963/8/75
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Two studies targeted physicians and patients using educa-
tional materials and feedback. The first achieved a small
reduction in antibiotic prescribing for acute respiratory
tract infections by delivering practice guidelines and per-
formance feedback to physicians, combined with mailing
educational materials to patient households and placing
information in waiting and examination rooms [26]. In
the second study, a significant increase in antidepressant
adherence was achieved by providing physicians with a
list of non-adherent patients, guidelines, and feedback on
their prescribing, along with mailing educational infor-
mation to patients initiating therapy and reminder letters
to non-adherent patients [27].
ii. Computerized real-time alerts
The common types of information technology used in
clinical care include electronic medical records, computer-
ized physician order entry, and real-time decision support
(such as reminders and prompts). Computerized order
entry with clinical decision support has been demon-
strated to improve prescribing and reduce medication
error rates [28]. Smith et al [29] used a computerized pro-
vider order entry system to provide prescribing alerts
regarding medicines with potential contraindications and
therapeutic alternatives. They found a reduction in dis-
pensing rates of potentially contraindicated medicines
(including tricyclic-antidepressants) among the elderly
(aged > 65 years). Another intervention of electronic
reminders to providers successfully increased the propor-
tion of female patients receiving osteoporosis medica-
tions or bone mineral density measurements; total
calcium intake, as a measure for quality of care, also
increased [30]. The addition of patient reminder letters
did not increase the impact of alerts alone on the target
outcomes [30].
Two studies in this review combined computerized alerts
and group academic detailing [31,32]. Interrupted time
series analyses demonstrated that computer-based drug-
specific and patient age-specific alerts were effective in
reducing prescribing of medications that interact with
warfarin [31] and the use of medications contraindicated
in the elderly [32]. In both studies, group education failed
to achieve any additional change in medication use over
the alerts alone.
iii. Reminders and telephone outreach
Bambauer et al [33] evaluated the impact of alerting pre-
scribers via faxed letters about patients who had gaps of
more than 10 days in refilling anti-depressant prescrip-
tions during the first six months of therapy. The faxed
alerts to prescribers had no discernable effect on the pro-
portion of non-adherent patients or the number of days
without antidepressant treatment during the 12-month
follow-up period.
The effectiveness of computerized reminders has also
been demonstrated to improve rates of recommended
laboratory drug monitoring. In two studies by Raebel et al
[34,35] daily computerized alerts identifying incomplete
laboratory tests for a range of drugs (such as amiodarone,
carbamazepine, and statins) were sent to pharmacists who
telephoned patients about the missing tests. This interven-
tion successfully increased the completion of laboratory
monitoring both at the initiation of and during the course
of drug therapy [34,35]. In contrast, neither non-intrusive
computerized alerts to physicians, nor presenting infor-
mation on computer screens without requiring additional
actions, were ineffective in changing laboratory monitor-
ing rates at the initiation of drug therapy [36].
A study by Feldstein et al [37] compared three interven-
tions to increase laboratory test completion for drugs pre-
scribed frequently in primary care. Electronic reminders to
providers about missing laboratory tests, with accompa-
nying sample letters for distribution to patients, were suc-
cessful in increasing the proportion of patients
completing tests; however, the impact was greater when
patients were contacted directly. Two other interventions
– reminding patients about incomplete tests via auto-
mated telephone voice message or telephone calls by
nurses – were both more effective than patient-specific
alerts to providers in increasing laboratory test comple-
tion [37].
Telephone outreach to patients by pharmacists was evalu-
ated in three papers. In one study [38,39] three monthly
telephone calls by pharmacists to monitor patients taking
antidepressants increased medication adherence and
improved depression symptoms, and not surprisingly,
increased patient feedback to pharmacists about medica-
tion use [38,39]. However, in the management of asthma,
three outreach telephone calls about five months apart
with tailored feedback to patients did not change medica-
tion or healthcare utilization [40].
Formulary interventions
i. Tiered formularies
Tiered formularies with different levels of patient copay-
ment to encourage use of preferred drugs are used increas-
ingly to enhance cost-effective use of medicines [41]. Six
papers in this review evaluated the impact of tiered formu-
lary changes.
Changing from a single copayment to a three-tier structure
reduced continuation of the original medications,
increased switching to agents in a lower tier, discontinued
use of all drugs in the affected class in some patients, and
decreased plan spending while increasing enrollee spend-
ing [42,43]. Similar but smaller effects were observed
when changing from a two-tier to a three-tier formularyBMC Health Services Research 2008, 8:75 http://www.biomedcentral.com/1472-6963/8/75
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[42]. These changes in the pattern of medication use were
seen in a number of prescription drug classes examined,
including angiotensin-converting enzyme inhibitors, stat-
ins, proton pump inhibitors, and medications for atten-
tion-deficit hyperactivity disorder [42,43]. A change from
two to three tiers decreased claims for third tier medica-
tions and net insurer costs, while patient out-of-pocket
copayments increased significantly in both the first year
[44] and second year [45] of follow-up. In a study by Nair
et al [46] change from a two-tier to a three-tier design
increased compliance of prescribers to preferred medica-
tions and increased overall medication use (primarily due
to increases in use of medications in the two lower tiers).
Patient cost-sharing (either in the form of fixed, percent,
or tiered copayments) is an important factor influencing
medication use. Roblin et al [47] showed that large (> $10
per 30-day supply) and moderate ($7–$10) increases in
cost-sharing attenuated an increasing trend of oral
hypoglycemic medication use by 18.5% and 9.2% respec-
tively over a 6-month period, while small ($1–$6)
increases in copayments had no impact.
ii. Prior authorization
Prior authorization (PA) policies are commonly used to
control drug utilization and cost [48]. In a health plan
that instituted a PA policy for COX-2 inhibitors, Hartung
et al [49] showed a significant reduction in COX-2 inhib-
itor use as well as a small decrease in use of gastrointesti-
nal protectants (e.g. proton pump inhibitors and
histamine-2 blockers) at one year post-intervention.
Another study demonstrated a reduction in pharmacy uti-
lization but an increase in medical utilization (particu-
larly hospitalization and emergency department visits)
after a COX-2 inhibitor PA policy was implemented [50].
iii. Formulary/coverage change
After vaginal anti-fungal products became available over-
the-counter, Gurwitz et al [51] showed a significant reduc-
tion in anti-fungal prescriptions. Studies by McDonough
et al [52] and Andrade et al [53] both evaluated the impact
of formulary switches between agents in the same thera-
peutic class and found increases in the prescribing of the
preferred agents (lisinopril and esterified estrogen tablets,
respectively). After loratidine became available as an over-
the-counter medication, Sullivan et al [54] found that pre-
scriptions decreased for both antihistamines and the total
category of allergic rhinitis medications (including
inhaled corticosteroids and leukotriene receptor antago-
nists) with a substantial reduction in pharmacy costs for
these medications. Antihistamine prescriptions were fur-
ther decreased by switching antihistamines to the third
formulary tier or by imposing a PA policy for these medi-
cations [54].
Two studies by Delate et al [55,56] evaluated the effects of
a formulary change with communication to physicians
and/or patients informing them of the change. The first
study evaluated the impact of notifying patients via mail
of impending formulary changes [56] and showed an
increase in subsequent formulary adherence. The second
study used letters to notify physicians and patients of for-
mulary changes and showed a small increase in conver-
sion of inefficient dosage regimens to a recommended
daily dosage of the same medication [55]. Similarly,
DeZearn et al [57] evaluated the effect of formulary
change with letters to prescribers encouraging the use of
generic cimetidine and found a reduction in prescriptions
for the brand name product and an increase in the pre-
scribing of generic cimetidine.
Collaborative care involving pharmacists
Collaboration of pharmacists in the care process has
emerged as a promising approach to improve quality of
care and patient outcomes [58]. Five studies in this review
that evaluated collaborative care interventions supported
evidence of effectiveness.
Finley et al [59] showed increases in antidepressant adher-
ence and small reductions in resource utilization when
pharmacists were used to titrate antidepressant doses,
under the supervision of psychiatrists. Okamoto et al [60]
demonstrated reduction in blood pressure and improve-
ment in patient quality of life (as measured by SF-36)
without increasing total costs per patient when pharma-
cists were responsible for educating patients, altering ther-
apy by administering more appropriate or less expensive
drugs to achieve similar or improved blood pressure con-
trol, and ordering laboratory tests as required. Another
study showed a significant increase in the proportion of
patients receiving screening and a reduction in total cho-
lesterol and low-density lipoprotein cholesterol levels
when pharmacists were responsible for monitoring and
titrating medications, and monitoring laboratory testing
[61]. Straka et al [62] evaluated the impact of collabora-
tion between pharmacists and providers in developing
patient-specific care plans which were followed by phar-
macists monitoring and educating patients. The interven-
tion was successful in reducing low-density lipoprotein
levels over the short-term and the effects persisted 18
months after discontinuation of the intervention; the pro-
portion of patients achieving the low-density lipoprotein
cholesterol goal also increased significantly [62]. Boren-
stein et al [63] evaluated the impact of a multifaceted pro-
gram involving individual and group education sessions
for physicians run by pharmacists, provision of a list of
patients with uncontrolled hypertension, individualized
patient education, monitoring by pharmacists, and hyper-
tension clinics to assess blood pressure and adherence to
antihypertensive medications. Treatment decisions byBMC Health Services Research 2008, 8:75 http://www.biomedcentral.com/1472-6963/8/75
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physicians considered assessment results and blood pres-
sure measures provided by pharmacists. This intervention
effectively reduced systolic blood pressure and increased
the proportion of patients achieving blood pressure goal
level [63]. A non-significant increase in total provider vis-
its (physician and pharmacist visits) was also observed
[63].
Disease management interventions
Disease management programs are structured, popula-
tion-based approaches for identifying, treating, and mon-
itoring persons with chronic illness. Generally, these are
multidisciplinary, integrated approaches aimed to
improve processes of care and patient outcomes [64].
Seven papers describing disease management interven-
tions that had pharmacotherapy as a primary focus were
included in this review.
i. Depression
Depression is a common medical condition that is associ-
ated with significant social and functional impairment as
well as high direct and indirect health care costs [65].
Research suggests depression can cause greater functional
disability than other chronic conditions such as diabetes,
chronic lung disease, and hypertension [66].
In one study, psychiatrists reviewed patient psychosocial
history and current depressive episodes over multiple ses-
sions. The intervention, which also included books and
videotapes for patient education and pharmacologic treat-
ment where necessary, effectively increased antidepres-
sant adherence at 12 months with modest improvements
in depression symptoms among severely depressed
patients [67]. Katon et al [68] evaluated an individualized
stepped-care depression treatment program provided by
specialist nurses working collaboratively with primary
care physicians for diabetic patients diagnosed with
depression. The intervention increased the use of ade-
quate antidepressant doses and drug adherence at 12
months; there were also modest improvements in depres-
sion symptoms and no change in diabetes outcomes [68].
Unutzer et al [69] evaluated a quality improvement inter-
vention targeting treatment of depression with follow-up
by specialist nurses. The intervention increased the pro-
portion of patients using antidepressants and antidepres-
sant use according to guideline-recommended doses
among patients at high risk for relapse. In the same study,
an intervention with a focus on quality of psychotherapy
rather than medication use was less successful than the
intervention targeting improved medication therapy [69].
Ray et al [70] examined the impact of transitioning
patients from traditional Medicare and MCOs to specialty
behavioral health organizations ('carve-out' programs).
They found a significant reduction in the proportion of
patients who continued antipsychotic therapy; this nega-
tive effect was greatest in high-risk patients.
ii. Asthma
Lozano et al [71] evaluated the impact of two interven-
tions: physician peer leader education within practice
groups and peer leader education coupled with nurse care
planning, telephone monitoring and follow-up of medi-
cation use, asthma symptoms and support for self-man-
agement. Both interventions effectively reduced asthma
symptoms and decreased the use of oral steroids; the
planned care intervention (multifaceted) had a greater
effect on these target outcomes than the group education
intervention [71]. However, at the practice-level, the two
intervention approaches did not differ in changes in the
proportion of patients using controller medications or
oral steroids, or in frequency of medical visits [72].
iii. Helicobacter pylori infection
Published guidelines recommend testing for HP in
patients receiving long-term acid suppression therapy for
acid-related disorders, and antibiotic treatment for those
with HP-positive peptic ulcer disease [73,74]. A test and
treat intervention for HP infection in patients receiving
long-term acid-reducing therapy successfully improved
gastrointestinal symptoms and reduced the use of acid-
reducing medications and associated costs at 12 months
[75]. Ofman et al [76] evaluated another test-and-treat
program for HP infection provided collaboratively by
physicians, pharmacists and nurses. This multifaceted
intervention involved local development and implemen-
tation of test-and-treat guidelines, individual and group
academic detailing, patient education by pharmacists, and
HP testing and medication monitoring by nurses. The
intervention successfully increased compliance with HP
testing and the proportion of patients prescribed appro-
priate anti-HP therapy at six months with no significant
change in total costs of related health services [76].
Discussion
There has been a substantial increase in published
research evaluating interventions targeting medication
use in managed care settings since our previous review [6].
This review identified 151 intervention studies in a six-
year publication period using a narrower inclusion criteria
(that is, disease management studies only included where
pharmacotherapy was a primary focus) compared with
105 studies over 35 years in our previous review (70 of
which were reported since 1996). Despite the increase in
research on this topic, a smaller proportion of published
studies met our criteria for methodological adequacy
(31% versus 46%). This failure to increase the degree of
methodological rigor in published research is of concern
because significant resources are used conducting studies
of poor methodological quality and such research mayBMC Health Services Research 2008, 8:75 http://www.biomedcentral.com/1472-6963/8/75
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produce scientifically invalid conclusions that influence
future research and policy. Although not a focus of this
review, we noted additional methodological issues apart
from research design. For example, the proxy measures of
adherence varied between studies (n = 10). Three studies
used the medication possession ratios [20,27,59], while
others measured the proportion of patients continuing
treatment [33,38,42,43,67,68,70]. The variability in
measures of adherence and infrequent reporting of this
important outcome in part reflects the well-known meth-
odological challenges in the measurement of adherence
[77].
Several findings from this report are consistent with our
previous review and the results of other systematic reviews
on the impact of interventions designed to change medi-
cation use. We once again confirmed that dissemination
of educational materials alone is ineffective and one-to-
one educational outreach visits are effective in increasing
adherence to prescribing guidelines [6,9,10,15,78]. Fur-
ther, this review confirms that multifaceted interventions
are more likely to be successful in changing medication
use than those using single strategies [6,10,78].
The current analysis, like other reviews, suggests group
education interventions may be beneficial but the find-
ings are inconclusive [78,79]. We found that peer leader
group education was effective in changing medication use
but was less effective than one-to-one academic detailing
[16,31,32]. The absence of incremental impact of group
education when combined with computer-based alerts, as
reported by Simon et al [32] and Feldstein et al [31], may
reflect the weakness of the approach or the superior effec-
tiveness of computerized alerts in changing the particular
outcomes targeted in these interventions.
Intervention approaches involving monitoring and feed-
back have been shown previously to produce small to
moderate effects on medication use [6,23,80], and this
review confirms these findings. Further, our review also
supports the existing literature regarding the short-term
effectiveness of real-time computer-based alerts in chang-
ing prescribing and test ordering [28,81]. However, most
studies in our review evaluated electronic medical record
systems with particular characteristics in a single HMO,
thus limiting the generalizability of findings. Only one
study [30] reported patient-relevant outcomes (namely,
quality of life measures).
Our review provides evidence that tiered formulary and
patient copayment interventions decrease non-preferred
drug use, reduce overall insurer costs, and increase patient
out-of-pocket expenses as intended. The use of prior
authorization policies resulted in similar effects. How-
ever, our findings concur with previous reviews in man-
aged care and other settings that these interventions may
also be associated with undesirable effects such as
increased rates of switching to other medications or dis-
continuation of essential and cost-effective medications
[3,48,82,83]. In addition, some studies reported changes
in measures such as hospitalization or medical resource
utilization (e.g. office visits) resulting from formulary-
related interventions [44,45,49,50,70].
Evidence from the literature suggests that coordinating
pharmacist services as a component of patient care
improves quality of care [84-86]. This review documents
positive results for collaborative care led by pharmacists,
including improved drug adherence and clinical out-
comes. Only some data on costs and resource use (e.g.
cost per mmHg of blood pressure decrease, average pro-
vider visit cost per patient) have been reported [59,60,63].
Finally, our findings confirm that disease management
interventions are associated with improvements in the
process and quality of care, both short and longer term
[87]. However, these disease management interventions
are by their nature multifaceted, and the type and number
of features within each disease management program vary
widely. Therefore, it is difficult to draw firm conclusions
about the contribution of individual components to the
overall impact.
There are several limitations to this review which need to
be acknowledged. Despite our intensive efforts to identify
all of the published literature on interventions to improve
the quality and efficiency of medication use in US man-
aged care settings, our search strategy may have missed
published articles. The full range of interventions cur-
rently used by managed care programs to influence use of
medicines is not covered by the studies in our review. For
example, no studies evaluated the impact of physician
incentives on prescribing, despite that fact that this strat-
egy is commonly used by MCOs. Further, our findings are
likely to be subject to under-reporting bias with interven-
tions showing no or negative effects, which are less likely
to be reported in the peer-reviewed literature. Even when
studies are published, many are methodologically inade-
quate; 69% of the studies identified in this review were
not included in the detailed analyses because of design
flaws. There are also fundamental difficulties in compar-
ing interventions with diverse objectives, intervention tar-
gets, measurement methods, and outcomes. Finally, it is
difficult to reach definitive conclusions about the contri-
bution of individual components to the overall effect of
multifaceted interventions.BMC Health Services Research 2008, 8:75 http://www.biomedcentral.com/1472-6963/8/75
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Future Directions
Despite the substantial number of interventions to
improve drug use in managed care, our understanding of
the impacts of these interventions is still limited.
First, a large proportion (40%) of the reviewed studies did
not detail the specifics of the managed care setting within
which the study was conducted. We found few studies
conducted in PPOs despite their prominent role in the US
managed care industry or in other "lightly" managed care
settings. The majority of studies in our review were con-
ducted in staff, group, or mixed-model HMOs, which rep-
resent more heavily managed settings. Future research
should establish whether intervention approaches that are
successful in such settings are also effective in more lightly
managed settings. Second, most studies in this review
used common surrogate outcome measures, such as pre-
scribing rates or proportions of patients achieving specific
medication use practices. Few studies reported medica-
tion adherence or patient-relevant outcomes such as clin-
ical status, hospitalization rates, or quality of life
measures. Furthermore, evidence about the cost-effective-
ness of most interventions is still quite limited. Cost-effec-
tiveness data are needed to select among many possible
strategies for improving medication use and associated
costs. Third, there is still a lack of publicly available, high
quality evidence concerning the effects of interventions
involving formulary changes or financial incentives,
which are commonly used to influence medication use.
Although the increased reporting of formulary-related
interventions is encouraging, the high prevalence of inad-
equate designs (e.g. pre-post without comparison group,
post-only) among studies of formulary-related interven-
tions (77%) is striking. An important conclusion to be
drawn from this review is that improvements in research
methodology will be essential in order to produce valid
and reliable study results about cost, quality of care, and
patient outcomes to inform managed care policy deci-
sions. It is highly likely these interventions do reduce costs
to the payer as they continue to be dominant in the man-
aged care environment. Evaluation of the patient-relevant
outcomes of formulary-related interventions is a research
priority. Finally, the durability of most of the intervention
effects reported in this review is uncertain because few
studies extend beyond two years follow-up and many
cover even shorter periods. In particular, further research
is needed to determine if computerized clinical support
systems are associated with improved patient outcomes
over the long-term.
Conclusion
There is good evidence for the effectiveness of several
strategies in changing drug use in the US managed care
setting. Policy makers have a solid and expanding knowl-
edge base to employ in the design of educational, moni-
toring and feedback, and collaborative care interventions
to improve medication use. Computerized alerts also
show promise in improving short-term outcomes. Despite
the wide use of formulary-related approaches to manag-
ing pharmaceutical use, there are still few well-designed
studies assessing their effects on patient outcomes. In
order to maximize health care cost-effectiveness while
containing costs, it is crucial to continue to promote rigor-
ous testing of interventions to improve medication use in
managed care settings in order to expand available high
quality evidence about their clinical and economic
impacts.
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